Review

celltrace violet dye c34571 (Thermo Fisher)

Thermo Fisher is a verified supplier

Thermo Fisher manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Thermo Fisher celltrace violet dye c34571
Celltrace Violet Dye C34571, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+violet+dye/celltrace+violet/pm40537284-160-32-40
Average 90 stars, based on 1 article reviews

celltrace violet dye c34571 - by Bioz Stars, 2026-09

90/100 stars

Images

Generated:

Article Title: Antibodies having specificity for BTN2 and uses thereof
Article Snippet: CD3+ T cells were sorted from healthy donor PBMCs by using the CD3+ Microbead kit (Miltenyi) according to manufacturer's instructions and frozen until the co-culture. .. Activated CD3+ T cells were generated as follow: CD3+ T cells were stained with 5 μM CellTrace Violet dye (ThermoFisher Scientific), then 105 such cells were cultured in X-Vivo 10 medium supplemented with 20 U/mL IL-2 (Miltenyi), LPS (200 ng/mL) and CountBright absolute counting beads (5×103 per well, ThermoFisher Scientific) in 96-well flat-bottom plates, previously coated with 1 μg/mL anti-CD3 mAb (clone OKT3, BD biosciences). ..

Staining:

Article Title: Safety, Efficacy and Total Cost of Point-of-care Manufactured anti-CD19 CAR T-cell Therapy in India: VELCART trial
Article Snippet: The peripheral blood mononuclear cells were isolated and stained with a standardized antibody panel based on previous studies.35 The data were analyzed using Kaluza analysis software v2.1 (Beckman Coulter) and Flow Jo v10.8.1 software (BD Biosciences). .. Target cells (CD19+ NALM6 cell line) or non-target cells (CD19K562 cell line) were stained with 0.5 μM concentration of CellTrace Violet dye (Thermo Fischer Scientific) according to the manufacturer’s instructions. ..

Article Title: Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial
Article Snippet: The data were analyzed using Kaluza analysis software v2.1 (Beckman Coulter) and Flow Jo v10.8.1 software (BD Biosciences). .. Target cells (CD19 + NALM6 cell line) or non-target cells (CD19- K562 cell line) were stained with 0.5 μM concentration of CellTrace Violet dye (Thermo Fischer Scientific) according to the manufacturer’s instructions. ..

Cell Culture:

Article Title: GFI1-driven transcriptional and epigenetic programs maintain CD8 + T cell stemness and persistence
Article Snippet: P14 T cells were isolated from the spleen of infected animals 5 days after infection using the BD FACSAria II (BD Biosciences) or Aurora CS Cell Sorter (Cytek Biosciences). .. The CD8 + T cells were labeled with 5 μM CellTrace Violet dye (Thermo Fisher) according to the manufacturer’s recommended protocol, and 5 × 10 3 T cells were cultured in complete RPMI 1640 medium. .. Complete RPMI medium was supplemented with either IL-2 (30 U ml −1 ; Thermo Fisher), IL-2 + IL-7 (10 ng ml −1 IL-7; Thermo Fisher) or IL-2 + CD3/CD28 beads (Dynabeads Mouse T-Activator CD3/CD28, Thermo Fisher).

other:

Article Title: Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis
Article Snippet: To assess proliferation and polarization, allogenic naïve pan T cells were labelled with 2.5 μM CellTrace CFSE or Violet (CTV) dye (Thermo Fisher) for 10 min at 37 C. For proliferation without polarization analysis, a total of 6 000 cells from sorted DC subsets were co-cultured with 30 000 CFSE-labelled allogeneic Pan T cells for five days.

Article Title: NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
Article Snippet: The following day, both wet- and dry-coated plates were washed twice with PBS (200 μL/well) before the addition of 100,000 cells/well (in 200 μL) of PBMCs stained with 5 μmol/L CellTrace Violet dye (Thermo Fisher Scientific, Cat. #C34557).

Labeling:

Article Title: Antibodies having specificity for CD38 and uses thereof
Article Snippet: For analysis of proliferation, T cells were labeled with CellTrace Violet dye (ThermoFisher) and subjected to stimulation with MM1.S cells or MM1.S-CD38KO with (or without) Bi38-3 (10 ng/mL) for 96 hours. .. For analysis of proliferation, T cells were labeled with CellTrace Violet dye (ThermoFisher) and subjected to stimulation with MM1.S cells or MM1.S-CD38KO with (or without) Bi38-3 (10 ng/mL) for 96 hours. .. Quantification of Cytokines in Cell Culture Supernatants The concentration of cytokines in supernatants from cytotoxicity assays were analyzed using the BDTM CBA Human Th1/Th2 Cytokine Kit II (Beckon Dickinson).

Article Title: Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Article Snippet: .. In preparation for the phagocytosis assay, 5 × 10E7 cells were labeled with CellTrace Violet dye (Thermo Fisher Scientific) per the manufacturer’s instructions. ..

Concentration Assay:

Phagocytosis Assay:

Image Search Results

CO-001 induces cancer cell phagocytosis via blocking the CD47 interaction with SIRPα and mediates direct PCCD. A, Jurkat cells (5 × 10 5 cells/mL) were incubated with 100 μg/mL human IgG4 isotype control, CO-001, B6H12, or 2D3, followed by incubation with 10 μg/mL FITC-conjugated SIRPα. B, CellTrace-labeled Jurkat cells co-cultured with DiO-labeled RAW264.7 macrophages and treated with CO-001, anti-CD47 sequence analogues AO-176 or magrolimab, benchmark anti-CD47 B6H12, or human IgG4 isotype control for 2 hours. C, Time-lapse imaging of Jurkat cells treated with the human IgG4 isotype control or CO-001 (1 μg/mL) at the indicated time points (H = hours) using the IncuCyte Live Cell Imaging System. Scale bar, 200 μm. D, Representative FACS plots showing Jurkat cells treated with 1 μg/mL the human IgG4 isotype control or CO-001 for 3 hours and then stained with annexin V and 7-AAD. The gated population, indicated by a red rectangle, indicates the population of the cells that is undergoing PCCD with 11% undergoing PCCD for IgG4-treated cells and 58% for CO-001 treated. E, Jurkat cells (5 × 10 5 cells/mL) were treated with CO-001 at the indicated concentrations in μg/mL or human IgG4 isotype control (1 μg/mL) for 0.5, 1, or 3 hours, followed by annexin V and 7-AAD staining. F, Reh cells (5 × 10 5 cells/mL) were treated with CO-001 or AO-176 at the indicated concentrations in μg/mL or human IgG4 isotype control (10 μg/mL) for 3 hours, followed by annexin V and 7-AAD staining. A , B , and E, Data presented as the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 relative to isotype control, §, P < 0.01, relative to the sample treated with CO-001 at the same concentration, n = 3 to 5. G, Binding of CO-001 to various cell lines derived from hematologic malignancies (Jurkat, MOLT-4, CCRF-CEM, and KG-1a) and RBCs relative to the human IgG4 isotype control. The EC 50 was determined using four-parameter curve fitting analysis in GraphPad Prism. H, Hemagglutination assay of freshly isolated RBCs (2% v/v in PBS) incubated with increasing concentrations of the CO-001, sequence analogues of AO-176 and magrolimab, or IgG4 isotype control. A small punctate circle indicates no hemagglutination, whereas a diffuse hazy pattern indicates hemagglutination. MFI, mean fluorescence intensity.

Journal: Molecular Cancer Therapeutics

Article Title: Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile

doi: 10.1158/1535-7163.MCT-24-0917

Figure Lengend Snippet: CO-001 induces cancer cell phagocytosis via blocking the CD47 interaction with SIRPα and mediates direct PCCD. A, Jurkat cells (5 × 10 5 cells/mL) were incubated with 100 μg/mL human IgG4 isotype control, CO-001, B6H12, or 2D3, followed by incubation with 10 μg/mL FITC-conjugated SIRPα. B, CellTrace-labeled Jurkat cells co-cultured with DiO-labeled RAW264.7 macrophages and treated with CO-001, anti-CD47 sequence analogues AO-176 or magrolimab, benchmark anti-CD47 B6H12, or human IgG4 isotype control for 2 hours. C, Time-lapse imaging of Jurkat cells treated with the human IgG4 isotype control or CO-001 (1 μg/mL) at the indicated time points (H = hours) using the IncuCyte Live Cell Imaging System. Scale bar, 200 μm. D, Representative FACS plots showing Jurkat cells treated with 1 μg/mL the human IgG4 isotype control or CO-001 for 3 hours and then stained with annexin V and 7-AAD. The gated population, indicated by a red rectangle, indicates the population of the cells that is undergoing PCCD with 11% undergoing PCCD for IgG4-treated cells and 58% for CO-001 treated. E, Jurkat cells (5 × 10 5 cells/mL) were treated with CO-001 at the indicated concentrations in μg/mL or human IgG4 isotype control (1 μg/mL) for 0.5, 1, or 3 hours, followed by annexin V and 7-AAD staining. F, Reh cells (5 × 10 5 cells/mL) were treated with CO-001 or AO-176 at the indicated concentrations in μg/mL or human IgG4 isotype control (10 μg/mL) for 3 hours, followed by annexin V and 7-AAD staining. A , B , and E, Data presented as the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 relative to isotype control, §, P < 0.01, relative to the sample treated with CO-001 at the same concentration, n = 3 to 5. G, Binding of CO-001 to various cell lines derived from hematologic malignancies (Jurkat, MOLT-4, CCRF-CEM, and KG-1a) and RBCs relative to the human IgG4 isotype control. The EC 50 was determined using four-parameter curve fitting analysis in GraphPad Prism. H, Hemagglutination assay of freshly isolated RBCs (2% v/v in PBS) incubated with increasing concentrations of the CO-001, sequence analogues of AO-176 and magrolimab, or IgG4 isotype control. A small punctate circle indicates no hemagglutination, whereas a diffuse hazy pattern indicates hemagglutination. MFI, mean fluorescence intensity.

Article Snippet: Target cancer cells were collected by centrifugation and stained with 1 μL/mL CellTrace Violet Cell Proliferation Dye according to the manufacturer’s protocol (Thermo Fisher Scientific, cat # C34557 ).

Techniques: Blocking Assay, Incubation, Control, Labeling, Cell Culture, Sequencing, Analogues, Imaging, Live Cell Imaging, Staining, Concentration Assay, Binding Assay, Derivative Assay, Hemagglutination Assay, Isolation, Fluorescence

Journal: Molecular Cancer Therapeutics

Article Title: Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile

doi: 10.1158/1535-7163.MCT-24-0917

Figure Lengend Snippet: Development of the CO-005 drug candidate with an improved RBC safety profile. A, Cartoon representation of the structure of the CO candidates CO-001, CO-004, and CO-005. B, Incubation of freshly isolated RBCs (2% v/v in PBS) with increasing concentrations of CO-001, CO-004, CO-005, or human IgG4 isotype control. A small punctate circle indicates no hemagglutination, whereas a diffuse hazy pattern indicates hemagglutination. C, Binding of CO-001, CO-005, CO-004, and human IgG4 isotype control to RBCs derived from a healthy human donor. D, Jurkat cells (5 × 10 5 cells/mL) were treated with CO-001, CO-004, or CO-005 at the indicated concentrations in μg/mL or human IgG4 isotype control (1 μg/mL) for 3 hours, followed by annexin V and 7-AAD staining. E, Phagocytosis activity of CO-001 fusion proteins in Jurkat cells using DiO-labeled RAW264.7 macrophages at the indicated concentrations for 2 hours. Phagocytosed target cells were analyzed by flow cytometry as %CellTrace + DiO + cells. D and E, Data are presented as the mean ± SD. Significance was determined by ANOVA analysis *, P < 0.01 relative to isotype control, §, P < 0.01, relative to the sample treated with CO-001 at the same concentration, n = 3 to 5. MFI, mean fluorescence intensity.

Techniques: Incubation, Isolation, Control, Binding Assay, Derivative Assay, Staining, Activity Assay, Labeling, Flow Cytometry, Concentration Assay, Fluorescence

(A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell proliferation was based on CellTrace Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).

Journal: PLOS Pathogens

Article Title: Fatty acid desaturases link cell metabolism pathways to promote proliferation of Epstein-Barr virus-infected B cells

doi: 10.1371/journal.ppat.1012685

Figure Lengend Snippet: (A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell proliferation was based on CellTrace Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).

Article Snippet: To track proliferation in early EBV-infected B cells, cells were stained with the fluorescent proliferation tracking dye CellTrace Violet (ThermoFisher, Cat# C34557 ).

Techniques: Infection

T-cell response after DEC-205 targeting. A , Antimouse DEC205 antibody conjugated to allophycocyanin was used to determine the proportion of cross-presenting dendritic cells (DCs). The overlay plots show the percentage of DCs from total DCs (black) expressing CD24, CD11c, XCR1, CD8α, and DEC205 (turquoise) in the spleen (left) and intra-abdominal lymph nodes (right). B , CellTrace Violet–stained CD8 + T cells from mice immunized with Ebola virus (EBOV) nucleoprotein (NP) peptide (YQVNNLEEI) and complete Freund adjuvant and boosted with the peptide and incomplete Freund adjuvant were incubated with bone marrow–derived DCs in the presence of 5 µg of the isotype control (left) or NP-DEC205 (middle). OT-I T cells incubated with bone marrow–derived DCs in the presence of 5 µg of ovalbumin DEC205 served as an internal positive control (right). Proliferation was assessed by flow cytometry. C , WT → IFNAR −/− mice (n = 3) were immunized with the isotype control or NP-DEC205. Fourteen days ( C ) or 28 days ( D ) later, splenocytes were collected and stimulated with EBOV NP AGQFLSFASLFLPKLVVGEK (CD4 T-cell) or RVIPVYQVNNLEEICQLIIQ (CD8 T-cell) peptides. Interferon-γ–secreting cells were enumerated; results are represented as spot-forming units per 5 × 10 5 cells. Bars represent mean values ± standard error of the mean. Statistical significance was determined using unpaired Student t test: ** P ≤ .01, *** P ≤ .001. Data are representative of 2 independent experiments. Abbreviations: DCs, dendritic cells; DEC-205, lymphocyte antigen 75; LNs, lymph nodes; NP, nucleoprotein; OVA, ovalbumin; SFU, spot-forming units.

Journal: The Journal of Infectious Diseases

Article Title: Antibody-Based Antigen Delivery to Dendritic Cells as a Vaccination Strategy Against Ebola Virus Disease

doi: 10.1093/infdis/jiae613

Figure Lengend Snippet: T-cell response after DEC-205 targeting. A , Antimouse DEC205 antibody conjugated to allophycocyanin was used to determine the proportion of cross-presenting dendritic cells (DCs). The overlay plots show the percentage of DCs from total DCs (black) expressing CD24, CD11c, XCR1, CD8α, and DEC205 (turquoise) in the spleen (left) and intra-abdominal lymph nodes (right). B , CellTrace Violet–stained CD8 + T cells from mice immunized with Ebola virus (EBOV) nucleoprotein (NP) peptide (YQVNNLEEI) and complete Freund adjuvant and boosted with the peptide and incomplete Freund adjuvant were incubated with bone marrow–derived DCs in the presence of 5 µg of the isotype control (left) or NP-DEC205 (middle). OT-I T cells incubated with bone marrow–derived DCs in the presence of 5 µg of ovalbumin DEC205 served as an internal positive control (right). Proliferation was assessed by flow cytometry. C , WT → IFNAR −/− mice (n = 3) were immunized with the isotype control or NP-DEC205. Fourteen days ( C ) or 28 days ( D ) later, splenocytes were collected and stimulated with EBOV NP AGQFLSFASLFLPKLVVGEK (CD4 T-cell) or RVIPVYQVNNLEEICQLIIQ (CD8 T-cell) peptides. Interferon-γ–secreting cells were enumerated; results are represented as spot-forming units per 5 × 10 5 cells. Bars represent mean values ± standard error of the mean. Statistical significance was determined using unpaired Student t test: ** P ≤ .01, *** P ≤ .001. Data are representative of 2 independent experiments. Abbreviations: DCs, dendritic cells; DEC-205, lymphocyte antigen 75; LNs, lymph nodes; NP, nucleoprotein; OVA, ovalbumin; SFU, spot-forming units.

Article Snippet: Splenocytes were labeled with the CellTrace Violet proliferation dye (Thermofisher Scientific) according to the manufacturer's instructions.

Techniques: Expressing, Staining, Virus, Adjuvant, Incubation, Derivative Assay, Control, Positive Control, Flow Cytometry